Abstract
Tumour cells can respond to targeted immune-cell therapies by losing proteins that mark them as being cancerous. Subverting this resistance mechanism may lead to more durable cancer-treatment strategies.
MeSH terms
-
Animals
-
Cell Dedifferentiation*
-
Humans
-
Immunotherapy*
-
Inflammation / pathology*
-
Melanoma / pathology*
-
Melanoma / therapy*
-
T-Lymphocytes, Cytotoxic / immunology*
-
T-Lymphocytes, Cytotoxic / transplantation*